超声心动图引导的心脏肿瘤的射频消融
Echocardiography-Guided Radiofrequency Ablation for Cardiac Tumors
影响因子:12.80000
分区:医学1区 Top / 心脏和心血管系统1区 肿瘤学1区
发表日期:2024 Aug
作者:
Junzhe Huang, Changhui Lei, David H Hsi, Minjuan Zheng, Hui Ma, Shengjun Ta, Rui Hu, Chao Han, Wenxia Li, Jing Li, Dong Qu, Fangqi Ruan, Jing Wang, Bo Wang, Xueli Zhao, Jiao Liu, Lina Zhao, Zhe Wang, Jian Yang, Liwen Liu
摘要
由于临床状况较差，患有心脏肿瘤的患者可能会对手术切除面临挑战。超声心动图指导的心脏肿瘤（TARFACT）的透射射频消融可能会提供一种侵入性的姑息治疗选项。这项研究旨在评估TARFACT的性和功效。患有心脏tar的安全性和有效性。心脏肿瘤患者（粘液脂肪症，脂肪性脂肪量，肿瘤肿瘤肿瘤肿瘤肿瘤肿瘤肿瘤肿瘤肿瘤肿瘤肿瘤肿胀肿瘤肿胀肿瘤肿胀肿块，肿瘤肿瘤肿胀肿块，包括心肌透明细胞肉瘤和心脏纹状瘤）。所有患者均接受了tarfact，并通过心电图，超声心动图成像，生化分析和病理确认进行评估。所有患者的中位随访时间为9（范围4-12）月。三名幸存的患者在最后一次随访（分别为9、12和12个月）还活着，而2例晚期肿瘤的患者分别存活了6个月和13个月后的TARFACT。 tarfact后，所有患者均显示出肿瘤大小的显着降低：平均长度从6.7±2.0 cm降低到4.7±1.8 cm（p = 0.007）；并且平均宽度从5.0±2.1 cm降至2.5±0.7 cm（p = 0.041）。 NYHA功能类别也有所改善：中位数（IQR）从3.0（1.5）降低到2.0（1.0）（p = 0.038），超声心动图上的电子波峰值的平均增加从64.4±15.7 cm/s升至76.6.6.6±18.6 cm/s（p = 0.008）和NT-PRO级别（p = 0.008）和NT-Pro bed revel（p = 0.008）（p = 0.008）。 （252.1）pg/ml至55.0（121.6）pg/ml（p = 0.043）。塔法克是心脏肿瘤的一种新型姑息治疗选择，减少了可及性肿瘤并改善了初步患者的临床症状。 （心脏肿瘤介入[射频/激光消融]治疗[CTIH]； NCT02815553）。
Abstract
Patients with cardiac tumors may present challenges for surgical resection due to poor clinical condition. Echocardiography-guided transapical radiofrequency ablation for cardiac tumors (TARFACT) potentially offers a less invasive palliative therapy option.This study aimed to evaluate the safety and efficacy of TARFACT.Five patients with cardiac tumors (mucinous liposarcoma, myocardial hypertrophy with inflammatory cell infiltration mass, fibrous tissue tumor hyperplasia, myocardial clear cell sarcoma, and cardiac rhabdomyoma) were included. All patients underwent TARFACT and were assessed with electrocardiogram, echocardiographic imaging, biochemical analysis, and pathological confirmation.The median follow-up for all patients was 9 (range 4-12) months. Three surviving patients were alive at their last follow-up (9, 12, and 12 months, respectively), whereas 2 patients with late-stage tumors survived 6 months and 13 months after TARFACT, respectively. After TARFACT, all patients showed significant reductions in tumor size: the mean length decreased from 6.7 ± 2.0 cm to 4.7 ± 1.8 cm (P = 0.007); and the mean width decreased from 5.0 ± 2.1 cm to 2.5 ± 0.7 cm (P = 0.041). NYHA functional class also improved: median (IQR) decreased from 3.0 (1.5) to 2.0 (1.0) (P = 0.038), Peak E-wave on echocardiography showed a mean increase from 64.4 ± 15.7 cm/s to 76.6 ± 18.6 cm/s (P = 0.008), and NT-pro BNP levels had a median (IQR) reduction from 115.7 (252.1) pg/mL to 55.0 (121.6) pg/mL (P = 0.043).TARFACT is a novel palliative treatment option for cardiac tumors, reducing accessible tumors and improving clinical symptoms in a preliminary group of patients. (Cardiac Tumors Interventional [Radio Frequency/Laser Ablation] Therapy [CTIH]; NCT02815553).